Senior Biostatistician (Oncology Clinical Studies)
Natera
Summary
This is an exciting opportunity for a Senior Biostatistician to support the adoption of Natera's oncology portfolio of innovative molecular diagnostic tests. You will contribute to the design, analysis, and reporting of oncology clinical trials while working closely with senior team members. You will assist in developing appropriate study designs and help generate insights that support the broader oncology portfolio.
Job description
The ideal candidate brings deep statistical expertise, strong scientific communication skills, and experience with applied statistics in a fast-paced, collaborative environment.
Primary Responsibilities
- Study Design and Statistical Strategy: Support the statistical design for oncology clinical utility studies. Provide technical expertise in complex study design methodologies and data analyses. With guidance, propose and justify efficient study designs tailored to complex oncology use cases.
- Cross-Functional Collaboration: Serve as study statistician for multiple studies. Collaborate with clinical, medical, and translational partners to influence study planning, development, and execution.
- Documentation and Reporting: Author and review high-quality statistical deliverables, including statistical analysis plans (SAPs), and reports (TLFs, CSRs, publications) for cross-functional collaborators and stakeholders.
- Innovation and Improvement: Recommend and apply novel statistical approaches where appropriate. Support continuous improvement of departmental processes, tools, and templates to enhance team efficiency and knowledge. Collaborate on manuscripts for publications.
Qualifications
- Advanced degree in Biostatistics, Statistics, or a related quantitative field (Ph.D. preferred).
- 0-2+ years of experience in clinical trial biostatistics.
- Expertise in time-to-event analysis, including handling of censoring, competing risks, and advanced survival modeling approaches commonly used in oncology.
- Proficient in R.
Knowledge, Skills, and Abilities
- Demonstrated ability and enthusiasm for working in fast-paced, cross-functional environments with collaborators from diverse technical backgrounds.
- Ability to communicate complex statistical concepts clearly to both technical and non-technical audiences.
- Preferred: Expertise with innovative study design (e.g. adaptive and biomarker-informed designs), power calculations, and endpoint evaluation.
- Preferred: Working knowledge of ICH and GCP guidelines as well as CDISC standards (e.g. SDTM, ADaM).
- Preferred: Experience with non-inferiority studies.
Requirements
- Advanced degree in Biostatistics, Statistics, or a related quantitative field (Ph.D. preferred)
- 0-2+ years of experience in clinical trial biostatistics
- Expertise in time-to-event analysis, including handling of censoring, competing risks, and advanced survival modeling approaches commonly used in oncology
- Proficient in R
- Demonstrated ability and enthusiasm for working in fast-paced, cross-functional environments with collaborators from diverse technical backgrounds
- Ability to communicate complex statistical concepts clearly to both technical and non-technical audiences
- Preferred: Expertise with innovative study design (e.g. adaptive and biomarker-informed designs), power calculations, and endpoint evaluation
- Preferred: Working knowledge of ICH and GCP guidelines as well as CDISC standards (e.g. SDTM, ADaM)
- Preferred: Experience with non-inferiority studies
Benefits
- Medical, Dental & Vision
- Life & Disability Insurance
- Free Testing
- Fertility Care Benefits
- Pregnancy & Baby Bonding Leave
- 401(k) Benefits
- Commuter Benefits
- Employee Referral Program
Company overview
Natera is a global leader in cell-free DNA (cfDNA) testing, specializing in molecular diagnostics for oncology, women's health, and organ health. Founded in 2004 and headquartered in Austin, Texas, the company has developed a cutting-edge cfDNA technology platform that combines novel molecular biology techniques with bioinformatics software and artificial intelligence. Natera's proprietary technology enables detection down to a single molecule in a tube of blood, making it possible to provide highly accurate genetic testing services. The company's flagship products include Signatera, a personalized circulating tumor DNA test for cancer monitoring; Panorama, a non-invasive prenatal test for chromosomal abnormalities; and Prospera, a transplant rejection assessment test. With over 4,400 employees and operations in CLIA-certified, CAP-accredited laboratories in Austin and San Carlos, California, Natera has processed more than 12 million tests and validated its technology through over 300 peer-reviewed publications. The company went public in 2015 and continues to innovate in precision medicine, aiming to make personalized genetic testing part of standard healthcare to enable earlier interventions and improved patient outcomes.